SCHEMBL2900931

SCHEMBL2900931

O=C(OCc1ccccc1)OC1CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
EPHX1 P07099 1/20 0.49
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
SGMS2 Q8NHU3 1/20 0.47
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
FABP7 O15540 1/20 0.46
FABP5 Q01469 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7459494 0.84 NMT1 (0.52) ALDH1A1SLC6A2SLC6A3TSHR
SCHEMBL2854195 0.84 CYP2C19 (0.49) ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2
SCHEMBL3936284 0.84 ALDH1A1 (0.45) ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2
SCHEMBL3936845 0.84 ALDH1A1 (0.45) ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2
SCHEMBL8316188 0.83 CHRNB2 (0.46) ALDH1A1KMT2ATSHR
SCHEMBL13402324 0.82 SCN1A (0.57) ALDH1A1KMT2AMEN1SLC6A3NPC1
SCHEMBL15843698 0.82 ALDH1A1 (0.46) ALDH1A1EPHX1KMT2AMEN1SGMS2
SCHEMBL15864914 0.82 ALDH1A1 (0.46) ALDH1A1EPHX1KMT2AMEN1SGMS2
SCHEMBL6027304 0.82 ALDH1A1 (0.60) ALDH1A1EPHX1KMT2AMEN1SGMS2
SCHEMBL15843697 0.82 ALDH1A1 (0.46) ALDH1A1EPHX1KMT2AMEN1SGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202990-A1 CYCLOHEXYL SUBSTITUTED TRIAZOLES HOFFMANN-LA ROCHE INC. (US) 2023-06-29 US disclosed
WO-2017173274-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-10-05 WO disclosed
EP-2217564-A1 COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE XenoPort, Inc. (US) 2010-08-18 EP disclosed
US-20090076147-A1 COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. 2009-03-19 US disclosed
WO-2009033054-A1 COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202990-A1 CYCLOHEXYL SUBSTITUTED TRIAZOLES AVPR1A, AVPR1B, AVPR2 ALDH1A1 3130/4885EPHX1 3712/4885KMT2A 2005/4885
US-20090076147-A1 COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE ADSL, SLC19A1, SLC25A21 ALDH1A1 1514/4885EPHX1 3143/4885KMT2A 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.